Cargando…
Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors
PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATER...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671553/ https://www.ncbi.nlm.nih.gov/pubmed/33201902 http://dx.doi.org/10.1371/journal.pone.0242093 |
_version_ | 1783610951816183808 |
---|---|
author | Bäumler, Wolf Schicho, Andreas Schaible, Jan Verloh, Niklas Senk, Karin Wiggermann, Phillip Stroszczynski, Christian Beyer, Lukas Phillip |
author_facet | Bäumler, Wolf Schicho, Andreas Schaible, Jan Verloh, Niklas Senk, Karin Wiggermann, Phillip Stroszczynski, Christian Beyer, Lukas Phillip |
author_sort | Bäumler, Wolf |
collection | PubMed |
description | PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATERIAL AND METHODS: The MRI-appearance of the ablation area was assessed 1–3 days, 6 weeks, 3 months, 6 months, 9 months and 1 year after IRE. The size of the ablation zone and signal intensities of each follow-up control were compared. Moreover, relationships between clinical features and the MRI-appearance of the ablation area 1–3 days after IRE were analyzed. RESULTS: The ablation zone size decreased from 5.6 ± 1.4 cm (1–3 days) to 3.7±1.2 cm (1 year). A significant decrease of central hypointensities was observed in T2-blade- (3 months), T2 haste- (6 weeks; 3 months; 6 months; 1 year), T1 arterial phase- (3 months; 1 year), and diffusion-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). The unenhanced T1-sequences showed significantly increasing central hypointensities (6 weeks; 3 months; 6 months; 9 months; 1 year). Significantly increasing peripheral hypointensities were detected in T1 arterial phase- (3 months; 6 months; 9 months; 1 year) and in T1 portal venous phase-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). Peripheral hypointensities of unenhanced T1-sequences decreased significantly 1 year after IRE. 1–3 days after IRE central T1 portal venous hypo- or isointensities were detected significantly more often than hyperintensities, if more than 3 IRE electrodes were used. CONCLUSION: Hepatic IRE results in continuous reduction of ablation zone size during the first postinterventional year. In addition to centrally decreasing T1-signal and almost steadily increasing signal in the enhanced T2 haste-, diffusion- and T1 arterial phase-sequences, there is a trend toward long-term decreasing T1 arterial- and portal venous MRI-signal intensity of the peripheral ablation area, probably representing a region of reversible electroporation. |
format | Online Article Text |
id | pubmed-7671553 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-76715532020-11-19 Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors Bäumler, Wolf Schicho, Andreas Schaible, Jan Verloh, Niklas Senk, Karin Wiggermann, Phillip Stroszczynski, Christian Beyer, Lukas Phillip PLoS One Research Article PURPOSE: To evaluate the appearance and size of ablation zones in gadoxetic-acid-enhanced magnetic resonance imaging (MRI) during the first year after irreversible electroporation (IRE) of primary or secondary hepatic malignancies and to investigate potential correlations to clinical features. MATERIAL AND METHODS: The MRI-appearance of the ablation area was assessed 1–3 days, 6 weeks, 3 months, 6 months, 9 months and 1 year after IRE. The size of the ablation zone and signal intensities of each follow-up control were compared. Moreover, relationships between clinical features and the MRI-appearance of the ablation area 1–3 days after IRE were analyzed. RESULTS: The ablation zone size decreased from 5.6 ± 1.4 cm (1–3 days) to 3.7±1.2 cm (1 year). A significant decrease of central hypointensities was observed in T2-blade- (3 months), T2 haste- (6 weeks; 3 months; 6 months; 1 year), T1 arterial phase- (3 months; 1 year), and diffusion-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). The unenhanced T1-sequences showed significantly increasing central hypointensities (6 weeks; 3 months; 6 months; 9 months; 1 year). Significantly increasing peripheral hypointensities were detected in T1 arterial phase- (3 months; 6 months; 9 months; 1 year) and in T1 portal venous phase-sequences (6 weeks; 3 months; 6 months; 9 months; 1 year). Peripheral hypointensities of unenhanced T1-sequences decreased significantly 1 year after IRE. 1–3 days after IRE central T1 portal venous hypo- or isointensities were detected significantly more often than hyperintensities, if more than 3 IRE electrodes were used. CONCLUSION: Hepatic IRE results in continuous reduction of ablation zone size during the first postinterventional year. In addition to centrally decreasing T1-signal and almost steadily increasing signal in the enhanced T2 haste-, diffusion- and T1 arterial phase-sequences, there is a trend toward long-term decreasing T1 arterial- and portal venous MRI-signal intensity of the peripheral ablation area, probably representing a region of reversible electroporation. Public Library of Science 2020-11-17 /pmc/articles/PMC7671553/ /pubmed/33201902 http://dx.doi.org/10.1371/journal.pone.0242093 Text en © 2020 Bäumler et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Bäumler, Wolf Schicho, Andreas Schaible, Jan Verloh, Niklas Senk, Karin Wiggermann, Phillip Stroszczynski, Christian Beyer, Lukas Phillip Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title | Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title_full | Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title_fullStr | Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title_full_unstemmed | Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title_short | Changes in gadoxetic-acid-enhanced MR imaging during the first year after irreversible electroporation of malignant hepatic tumors |
title_sort | changes in gadoxetic-acid-enhanced mr imaging during the first year after irreversible electroporation of malignant hepatic tumors |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671553/ https://www.ncbi.nlm.nih.gov/pubmed/33201902 http://dx.doi.org/10.1371/journal.pone.0242093 |
work_keys_str_mv | AT baumlerwolf changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT schichoandreas changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT schaiblejan changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT verlohniklas changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT senkkarin changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT wiggermannphillip changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT stroszczynskichristian changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors AT beyerlukasphillip changesingadoxeticacidenhancedmrimagingduringthefirstyearafterirreversibleelectroporationofmalignanthepatictumors |